Resumen
Combinations of chemotherapeutic agents are commonly used in the clinical setting as this allows for a reduction in the dose of each agent, and thus reduced toxicity, with increased therapeutic efficacy. This study proved the feasibility of synergy between two novel oestrone analogues and GLUT inhibitors. The synergistic combinations which have been identified indicate that the different molecular subtypes of breast cancer, as represented by the cell lines used, respond differently to the combination therapy. These differences will be further investigated.